Ganitumab

Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer[1].

Research Areas >> Cancer

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> IGF-1R

Ganitumab (AMG 479; 0.032-500 nM; 10 分钟; CT26 细胞) 结合 mIGF1R 并抑制 IGF1 和 IGF2 介导的 mIGF1R 的激活[1]。 Western Blot Analysis[1] Cell Line: CT26 cells Concentration: 0.032-500 nM Incubation Time: 10 minutes Result: Inhibited IGF1-induced autophosphorylation of mIGF1R in CT26 murine colon carcinoma cells in a dose-dependent manner.

Ganitumab (AMG 479; 1 mg/剂; i.p; Naïve 和荷瘤小鼠) 抑制 IGF1 诱导的小鼠肺中 mIGF1R 的激活[1]。 Ganitumab (300 μg/剂; i.p.; 雌性无胸腺裸鼠) 减少外周血中性粒细胞[1]。 Ganitumab (300 μg/剂; i.p.;雄性无胸腺裸鼠) 导致雄性小鼠糖耐量受损，并增加血清中 mGH，mIGF1 和 mIGFBP3[1]。 Animal Model: Naïve and tumor-bearing mice[1] Dosage: 1 mg/dose Administration: Intraperitoneal injection Result: Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth. Animal Model: Male athymic nude mice[1] Dosage: 300 μg/dose Administration: Intraperitoneal injection, twice per week for a total of five doses Result: Had significantly higher serum glucose levels than hIgG1-pretreated mice. Increased serum levels of mIGF1, mIGFPB3 and mGH. Animal Model: Female athymic nude mice[1] Dosage: 300 μg/dose Administration: Intraperitoneal injection, twice per week for a total of five doses Result: Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls.

[1]. Moody G, et, al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol. 2014 Mar 17;221(1):145-55.